Table 3.
Median OS and 1-year, 2-year and 3-year OS rates
| mOS (months) (95% CI) | 1-year OS (%; 95% CI) |
2-year OS (%; 95% CI) |
3-year OS (%; 95% CI) |
|
| All patients | 19 (15.9 to 22.0) | 69 (63.5 to 74.5) | 41.1 (34.9 to 47.9) | 30.1 (22.2 to 37.9) |
| Number of MBM | ||||
| 1–3 | 29 (16.9 to 41.4) | 71.2 (63.6 to 78.8) | 57.0 (46.8 to 67.2) | 42.3 (28.6 to 56.0) |
| >3 | 14 (10.2 to 17.9) | 52.1 (44.3 to 59.9) | 32.2 (23.9 to 40.4) | 22.7 (13.5 to 31.9) |
| BRAF status | ||||
| BRAF wild type | 19 (14.9 to 23.0) | 61.3 (51.9 to 70.7) | 40.1 (28.3 to 51.9) | N/A |
| BRAF mutant | 18 (14.1 to 21.9) | 60.7 (53.8 to 67.6) | 42.0 (34.2 to 49.8) | 27.3 (18.1 to 36.5) |
| LDH level | ||||
| Normal | 21 (15.1 to 26.9) | 69.3 (61.6 to 76.7) | 45.9 (36.3 to 55.5) | 32.6 (20.4 to 44.6) |
| Elevated | 19 (12.8 to 25.1) | 58.4 (48.8 to 68.0) | 40.1 (29.1 to 51.1) | 32.9 (19.9 to 45.8) |
| 2×>ULN | 7 (6.1 to 7.9) | 32.1 (17.6 to 46.6) | 22.9 (8.0 to 37.8) | 8.6 (5.5 to 22.7) |
| S100B level | ||||
| Normal | 22 (18.2 to 25.8) | 78.4 (68.6 to 88.2) | 44.7 (30.8 to 58.6) | 36.1 (20.6 to 51.6) |
| Elevated | 17 (9.6 to 24.4) | 57.0 (48.2 to 65.8) | 42.8 (32.8 to 52.8) | 32.3 (20.5 to 44.6) |
| 10×>ULN | 17 (8.2 to 25.8) | 53.5 (40.4 to 66.6) | 30.9 (15.8 to 45.9) | 20.6 (1.2 to 40.0) |
| Best intracerebral response | ||||
| CR | Not reached | 92.7 (82.9 to 100) | 85.6 (69.3 to 100) | N/A |
| PR | 42 (22.6 to 61.4) | 86.9 (76.9 to 96.9) | 62.9 (46.0 to 79.8) | 55.1 (34.5 to 75.7) |
| SD | Not reached | 93.6 (86.5 to 100) | 83.6 (71.1 to 96.1) | 50.2 (19.0 to 81.4) |
| PD | 10 (16.7 to 23.3) | 39.0 (31.4 to 46.6) | 20.0 (13.1 to 26.9) | 12.8 (6.0 to 19.3) |
| CombiIT | ||||
| First line | 17 (10.7 to 23.9) | 56.4 (48.9 to 63.8) | 44.7 (35.9 to 53.5) | 27.9 (11.2 to 44.6) |
| Not first line | 21 (17.8 to 24.2) | 67.9 (59.9 to 75.9) | 41.9 (32.7 to 51.1) | 31.6 (21.8 to 41.4) |
| BRAF mutant patients | ||||
| First-line targeted therapy | 22 (17.2 to 26.77) | 65.6 (55.2 to 76) | 44.3 (34.5 to 57.7) | 32.0 (20 to 44) |
| First-line CombiIT | 16 (7 to 25) | 53.6 (43.2 to 64) | 42.9 (30.7 to 55.1) | N/A |
| BRAF wild-type patients | ||||
| First-line CombiIT | 21 (10.2 to 31.8) | 59.6 (52.6 to 73.4) | 47 (33.8 to 60.1) | 47 (33.8 to 60.1) |
| First-line not CombiIT | 19 (16.3 to 21.7) | 68.3 (50.1 to 74.2) | 31.9 (11.5 to 52.3) | 31.9 (11.5 to 52.3) |
| STR/surgery (at any time point) | ||||
| Yes | 24 (19.6 to 28.4) | 70.6 (63.7 to 77.5) | 49.5 (40.9 to 58.1) | 36.5 (26.3 to 46.7) |
| No | 16 (7.6 to 24.4) | 53.2 (41.0 to 65.4) | 40.9 (26.6 to 55.2) | N/A |
| WBRT | 8 (4.9 to 11.0) | 40.7 (28.4 to 53.0) | 20.8 (9.4 to 32.2) | 10.4 (1.4 to 22.2) |
| STR/surgery | ||||
| Upfront | 26 (21.1 to 30.9) | 72.5 (65.1 to 79.9) | 50.9 (41.3 to 60.5) | 39.5 (28.3 to 50.7) |
| Later | 16 (10.8 to 21.2) | 63.7 (47.6 to 79.8) | 44.3 (24.9 to 63.7) | 22.2 (1.5 to 45.9) |
| ECOG-PS | ||||
| 0 | 22 (16.4 to 27.6) | 65.7 (59.0 to 72.4) | 47.1 (39.1 to 55.1) | 36.4 (26.4 to 46.4) |
| 1 | 18 (7.3 to 28.7) | 52.3 (40.1 to 64.5) | 38.0 (34.1 to 519) | 22.2 (6.1 to 38.3) |
| >1 | 8 (7.3 to 17.1) | 49.3 (31.8 to 66.7) | 23.5 (5.5 to 41.5) | 5.9 (5.1 to 16.9) |
| Presence of symptomatic MBM | ||||
| No | 19 (10.7 to 27.2) | 62.5 (53.4 to 71.8) | 45.4 (34.6 to 56.2) | 35.1 (21.8 to 48.4) |
| Yes | 12 (7.0 to 17.0) | 46 (32.1 to 59.9) | 28.1 (13.8 to 42.4) | 15.0 (0 to 30.7) |
CombiIT, nivolumab plus ipilimumab; CR, complete response; ECOG-PS, Eastern Cooperative Oncology Group performance status; MBM, melanoma brain metastases; mOS, median overall survival; PD, progressive disease; PR, partial response; SD, stable disease; STR, stereotactic radiosurgery; ULN, upper level normal; WBRT, whole brain radiotherapy.